Trial Profile
Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Talazoparib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2023 Status changed from active, no longer recruiting to completed.
- 28 Jan 2022 Results published in the Clinical Cancer Research
- 25 Nov 2020 Status changed from recruiting to active, no longer recruiting.